VAN-RIZATRIPTAN ODT TABLET (ORALLY DISINTEGRATING)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

RIZATRIPTAN (RIZATRIPTAN BENZOATE)

متاح من:

VANC PHARMACEUTICALS INC

ATC رمز:

N02CC04

INN (الاسم الدولي):

RIZATRIPTAN

جرعة:

5MG

الشكل الصيدلاني:

TABLET (ORALLY DISINTEGRATING)

تركيب:

RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

6

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

SELECTIVE SEROTONIN AGONISTS

ملخص المنتج:

Active ingredient group (AIG) number: 0137841001; AHFS:

الوضع إذن:

CANCELLED PRE MARKET

تاريخ الترخيص:

2019-07-31

خصائص المنتج

PRODUCT MONOGRAPH
PR
VAN-RIZATRIPTAN ODT
Rizatriptan Benzoate Orally Disintegrating Tablets
5 mg and 10 mg Rizatriptan (as Rizatriptan Benzoate)
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Vanc Pharmaceuticals Inc.
Date of Preparation:
210-2639, Viking way 9 November, 2015
Richmond, BC V6V3B7
www.vancpharm.com
Submission Control No: 188668
_ _
_VAN-Rizatriptan ODT _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
..............................................................................................................
12
DRUG INTERACTIONS
...............................................................................................................
18
DOSAGE AND ADMINISTRATION
...........................................................................................
20
OVERDOSAGE
.............................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
22
STORAGE AND STABILITY
......................................................................................................
25
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 26
PART II: SCIENTIFIC INFORMATION